| 5.82 -0.04 (-0.68%) | 06-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.79 |
1-year : | 8.67 |
| Resists | First : | 6.66 |
Second : | 7.42 |
| Pivot price | 5.92 |
|||
| Supports | First : | 5.44 | Second : | 4.52 |
| MAs | MA(5) : | 5.92 |
MA(20) : | 5.96 |
| MA(100) : | 7.32 |
MA(250) : | 7.52 |
|
| MACD | MACD : | -0.3  |
Signal : | -0.4 |
| %K %D | K(14,3) : | 35.2 |
D(3) : | 40.4 |
| RSI | RSI(14): 39.5 |
|||
| 52-week | High : | 9.42 | Low : | 5.44 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ GYRE ] has closed above bottom band by 35.7%. Bollinger Bands are 41.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5.94 - 5.98 | 5.98 - 6.02 |
| Low: | 5.64 - 5.69 | 5.69 - 5.73 |
| Close: | 5.75 - 5.83 | 5.83 - 5.89 |
Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease. The company's pipeline further includes F351 (Hydronidone), a compound structurally related to ETUARY. F351 is currently in Phase 3 studies for chronic hepatitis B-induced liver fibrosis and is in Phase 1 trials for liver fibrosis associated with nonalcoholic associated steatohepatitis (NASH). Other programs in development feature F573, which is progressing through Phase 2 studies for acute and acute-on-chronic liver failure. Additionally, two early-stage candidates, F528 and F230, are in preclinical development, focusing on chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH), respectively. Established in 2002, Gyre Therapeutics, Inc. is based in San Diego, California, and operates as a subsidiary of GNI USA, Inc.
Tue, 16 Jun 2026
Gyre Therapeutics stockholders approve all proposals at annual meeting - Investing.com
Mon, 15 Jun 2026
Gyre COO Ye Weiguo sells $17,276 in company stock - Investing.com
Mon, 15 Jun 2026
Gyre Therapeutics (GYRE) COO sells 2,800 shares after exercising options - Stock Titan
Sat, 13 Jun 2026
GYRE Q1 2026 Earnings: EPS Surprises to the Upside, Revenue Not Reported, Stock Slips - Adjusted Earnings Analysis - lwvtexas.org
Thu, 11 Jun 2026
Gyre Therapeutics (GYRE) COO sells 20,918 shares after exercising options - Stock Titan
Wed, 10 Jun 2026
Gyre Therapeutics (GYRE) awards GC 50,000 options at $6.05 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 97 (M) |
| Shares Float | 21 (M) |
| Held by Insiders | 86.3 (%) |
| Held by Institutions | 3.7 (%) |
| Shares Short | 1,670 (K) |
| Shares Short P.Month | 1,580 (K) |
| EPS | -0.08 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.11 |
| Profit Margin | -5.5 % |
| Operating Margin | -30.3 % |
| Return on Assets (ttm) | 1 % |
| Return on Equity (ttm) | -3.1 % |
| Qtrly Rev. Growth | 2 % |
| Gross Profit (p.s.) | 1.14 |
| Sales Per Share | 1.2 |
| EBITDA (p.s.) | 0.05 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 4 (M) |
| Levered Free Cash Flow | 10 (M) |
| PE Ratio | -72.75 |
| PEG Ratio | 0 |
| Price to Book value | 5.24 |
| Price to Sales | 4.82 |
| Price to Cash Flow | 130.72 |
| Dividend | 3.59 |
| Forward Dividend | 0 |
| Dividend Yield | 61.8% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|